Advertisement

The Evaluation of Surrogate Endpoints

  • Tomasz Burzykowski
  • Geert Molenberghs
  • Marc Buyse

Part of the Statistics for Biology and Health book series (SBH)

Table of contents

  1. Front Matter
    Pages i-xxiii
  2. Geert Molenberghs, Marc Buyse, Tomasz Burzykowski
    Pages 1-5
  3. Geert Molenberghs, Marc Buyse, Tomasz Burzykowski
    Pages 7-12
  4. Geert Molenberghs, Marc Buyse, Tomasz Burzykowski
    Pages 53-65
  5. Geert Molenberghs, Marc Buyse, Tomasz Burzykowski
    Pages 67-82
  6. Geert Molenberghs, Marc Buyse, Tomasz Burzykowski
    Pages 95-120
  7. José Cortiñas Abrahantes, Tomasz Burzykowski, Geert Molenberghs
    Pages 121-141
  8. Didier Renard, Helena Geys
    Pages 153-162
  9. Tomasz Burzykowski, José Cortiñas Abrahantes
    Pages 163-194
  10. Tomasz Burzykowski
    Pages 195-217
  11. Ariel Alonso Abad, Helena Geys, Tony Vangeneugden
    Pages 231-251
  12. Ziv Shkedy, Franz Torres Barbosa
    Pages 253-270
  13. Tony Vangeneugden, Ariel Alonso Abad, Helena Geys, Annouschka Laenen
    Pages 271-293
  14. Tomasz Burzykowski, Marc Buyse
    Pages 323-340
  15. Arthur Schatzkin, Mitch Gail, Laurence Freedman
    Pages 349-366
  16. Back Matter
    Pages 367-408

About this book

Introduction

Both humanitarian and commercial considerations have spurred intensive search for methods to reduce the time and cost required to develop new therapies. The identification and use of surrogate endpoints, i.e., measures that can replace or supplement other endpoints in evaluations of experimental treatments or other interventions, is a general strategy that has stimulated both enthusiasm and skepticism. Surrogate endpoints are useful when they can be measured earlier, more conveniently, or more frequently than the "true" endpoints of primary interest. Regulatory agencies around the globe, particularly in the United States, Europe, and Japan, are introducing provisions and policies relating to the use of surrogate endpoints in registration studies. But how can one establish the adequacy of a surrogate? What kind of evidence is needed, and what statistical methods portray that evidence most appropriately?

This book offers a balanced account on this controversial topic. The text presents major developments of the last couple of decades, together with a unified, meta-analytic framework within which surrogates can be evaluated from several angles. Methodological development is coupled with perspectives on various therapeutic areas. Academic views are juxtaposed with standpoints of scientists working in the biopharmaceutical industry as well as of colleagues from the regulatory authorities.

Tomasz Burzykowski is Assistant Professor of Biostatistics at the Limburgs Universitair Centrum in Belgium. Dr. Burzykowski has published methodological work on the analysis of survey data, meta-analyses of clinical trials, and validation of surrogate endpoints. He is a co-author of numerous papers applying statistical methods to clinical data in different disease areas (cancer, cardiovascular diseases, dermatology, orthodontics).

Geert Molenberghs is Professor of Biostatistics at the Limburgs Universitair Centrum in Belgium. Dr. Molenberghs published methodological work on surrogate markers in clinical trials, categorical data, longitudinal data analysis, and on the analysis of non-response in clinical and epidemiological studies. He serves as Joint Editor for Applied Statistics (2001-2004) and is President of the International Biometric Society (2004-2005). He was elected Fellow of the American Statistical Association and received the Guy Medal in Bronze from the Royal Statistical Society.

Marc Buyse founded the International Drug Development Institute in 1991. He is Past President of the International Society for Clinical Biostatistics, Past President of the Quetelet Society, and Past Board Member of the Society for Clinical Trials. He is currently the Executive Director of IDDI (International Drug Development Institute) and Associate Professor of biostatistics at the Limburgs Universitair Centrum, Center for Statistics, Diepenbeek, Belgium. He has published extensively in the fields of biostatistics and oncology. His research interests include meta-analysis, surrogate endpoints, statistical detection of fraud, and the design and statistical analysis of clinical trials.

Keywords

cancer data analysis dermatology diseases oncology statistics therapy

Editors and affiliations

  • Tomasz Burzykowski
    • 1
  • Geert Molenberghs
    • 1
  • Marc Buyse
    • 2
  1. 1.Center for StatisticsLimburgs Universitair CentrumDiepenbeekBelgium
  2. 2.International Drug Development InstituteBrusselsBelgium

Bibliographic information

  • DOI https://doi.org/10.1007/b138566
  • Copyright Information Springer Science+Business Media, Inc. 2005
  • Publisher Name Springer, New York, NY
  • eBook Packages Mathematics and Statistics
  • Print ISBN 978-0-387-20277-8
  • Online ISBN 978-0-387-27080-7
  • Series Print ISSN 1431-8776
  • Buy this book on publisher's site